Consensus Enliven Therapeutics, Inc.

Equities

ELVN

US29337E1029

Market Closed - Nasdaq Other stock markets 03:59:45 2024-05-29 pm EDT			5-day change	1st Jan Change
21.32 ^USD	-8.18%		-6.86%	+54.05%

May. 20	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing	MT
May. 14	Enliven Therapeutics Q1 Loss Narrows	MT

Evolution of the average Target Price on Enliven Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4fb70187e07ec3c9d842a6346.mChVok4shbAWpSFnPL3TJN0BbLnAqNQWlJMaTV1Z8ik.rG8hk3tqyeVw8mwLdcmyF69EBpSO5-xRoaVpIAoUlkPZZhTmeB7U2F_2ZA~b06e99ee2bc865b2bf2b7f58cf37acd4

Analyst Recommendations on Enliven Therapeutics, Inc.

Mizuho Securities Initiates Enliven Therapeutics With Buy Rating, Price Target is $34	Apr. 09	MT
Jefferies Initiates Enliven Therapeutics at Buy With $27 Price Target	23-03-29	MT
TD Cowen Starts Enliven Therapeutics at Outperform	23-03-03	MT